跳至主要内容
临床试验/NCT06570733
NCT06570733进行中(未招募)不适用

Acceptability Research on Integrated Point of Care Sexually Transmitted Infection (STI) Testing and Expedited Partner Therapy (EPT)

Wits RHI Research Centre Clinical Research Site1 个研究点 分布在 1 个国家目标入组 305 人开始时间: 2022年2月11日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
305
试验地点
1
主要终点
GeneXpert

研究概览

简要总结

This protocol builds on nearly a decade of collaborative HIV/STI prevention research to conduct a prospective cohort study of Adolescent Girls and Young Women (AGYW) eligible for PrEP in South Africa in which we will assess the acceptability of point-of-care STI testing plus Expedited Partner Therapy (EPT) and its impact on the incidence of common curable STIs over 12 months of follow-up. The social-behavioral scientist will undertake qualitative interviews with participants and their male partners to identify facilitators and barriers to EPT uptake and conduct a comparative cost analysis to estimate the cost per person tested using point-of-care STI testing with and without EPT incremental to the cost of standard of care. Findings from the proposed research will provide essential knowledge for national policymakers to advance approaches to STI screening and treatment that will lead to improvements in AGYW sexual reproductive health and reductions in STIs. The data generated from this project are essential to inform efforts to reduce the burden of STIs and HIV-1 in women and achieve the 2030 Sustainable Development Goals, which includes substantial reductions in HIIV and STIs in key at-risk populations. This project will support global efforts to substantially reduce STIs in key populations.

详细描述

The study aims to estimate the incidence of STIs (Chlamydia trachomatis, Neisseria gonorrhea, and Trichomoniasis vaginalis) among Adolescent Girls and Young Women (AGYW) initiating PrEP who received point-of-care STI testing plus Expedited Partner Therapy (EPT) and those who received point-of-care STI testing but declined EPT. To assess the acceptability of point-to-care STI testing plus EPT for AGYW initiating oral PrEP and its impact on exposure to social harms. To assess the male partner's response and acceptability among those who received EPT. Estimate the cost of implementing rapid point-of-care diagnostic STI testing and EPT for AGYW in South Africa using PrEP compared to standard syndromic management. The study design aims to conduct a prospective cohort study among adolescent girls and young women (AGYW) and assess the incidence of select STIs detected by point-of-care testing, including C.trachomatis, N. gonorrhea, or T. vaginalis, over 12 months of follow-up. Moreover, to assess the acceptability of expedited partner treatment offered to AGYW with an STI and their partners who received EPT. To conduct a comparative cost analysis to estimate the cost per person tested using point-of-care STI testing with and without EPT incremental to the standard cost.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
16 Years 至 25 Years(Child, Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •Cisgender girls and women (16-25 years of age, inclusive)
  • •Vaginal sex with a cisgender male partner in the last three months
  • •CT, GC, or TV detected at screening
  • •Willing to return for quarterly study visits
  • •Not currently pregnant and not planning to become pregnant in the next 12 months
  • •Using or willing to initiate a highly effective method of contraception*
  • •HIV-uninfected
  • •Interested in initiating oral PrEP
  • •No known contraindications to FTC or TDF

排除标准

  • •At Screening or Enrollment, participant reports known adverse reaction to FTC or TDF.
  • •At Screening or Enrollment, has single or dual rapid Antibody positive reactive HIV-1 test.
  • •At Screening or Enrollment, is already participating in another research study involving drugs, medical devices, or vaccines for STI prevention or treatment.
  • •As determined by the PIs/designee, any current or historical physical health, mental health or social issue or condition that the site investigator or designee determines should exclude participation.
  • •Has any other condition that, in the opinion of the PIs/designee, would preclude informed consent, make study participation unsafe, or otherwise interfere with achieving the study objectives.

结局指标

主要结局

GeneXpert

时间窗: 2 years

A PCR instrument used to diagnose chlamydia trachomatis and gonorrhea.

次要结局

  • Osom rapid testing kit(2 years)

研究者

发起方
Wits RHI Research Centre Clinical Research Site
申办方类型
Other
责任方
Principal Investigator
主要研究者

Thesla Palanee-Phillips

Director of Clinical Trials

Wits RHI Research Centre Clinical Research Site

研究点 (1)

Loading locations...

相似试验